Chronic hepatitis B virus infection: Review and update

Davydov, Liya
June 2007
Drug Topics;6/18/2007, Vol. 151 Issue 12, p51
Trade Publication
The article reports on the drugs approved by the U.S. Food and Drug Administration for the treatment of chronic hepatitis B (HBV). Lamivudine inhibits viral replication, suppress HBV DNA levels and normalizes the alanine aminotransferase (ALT) levels of the patients. Adefor dipivoxil manages positive and negative types of HBV and functions similar to lamivudine. Entecavir has similar effects with lamivudine and effective for patients who are coinfected with HIV. Telbivudine manages both positive and negative HBV, and improves the histological analysis. Interferon alfa-2b and peginterferon alfa-2a both suppress viral replication via their immunomodulatory properties.


Related Articles

  • Hep B patients anxious for Adefovir. Getty, Jeff // Bay Area Reporter;9/6/2001, Vol. 31 Issue 36, p15 

    Reports on the status of the application for the U.S. Food and Drug Administration's approval of the antiviral drug Adefovir for the treatment of hepatitis B. Number of Americans infected with the disease; Improvement in blood markers and liver functions; Access to drugs through expanded access...

  • Spring Bank Targets Hepatitis B Market with Small-Molecule Tech. Powers, Marie // BioWorld Today;6/3/2011, Vol. 22 Issue 107, p1 

    The article reports on the application of Spring Bank Pharmaceuticals Inc. for an investigational new drug (IND) with the U.S. Food and Drug Administration (FDA). It makes reference to the SB 9200 drug for hepatitis B based on the small molecule nucleic acid hybrid (SMNH) technology of the...

  • WASHINGTON, D.C.-FDA approves new drugs for hepatitis B.  // Gay & Lesbian Times;11/9/2006, Issue 985, p33 

    The article reports that the U.S. Food and Drug Administration has approved Tyzeka (telbivudine) for use in treating adults with chronic hepatitis B. The drug can suppress the hepatitis B virus and reduce the liver inflammation that comes with the disease. Tyzeka was developed by Idenix...

  • Adherence to Chronic Hepatitis B Treatment Guideline Recommendations for Laboratory Monitoring of Patients Who Are Not Receiving Antiviral Treatment. Juday, Timothy; Hong Tang; Harris, Melissa; Powers, Annette Z.; Kim, Edward; Hanna, George J. // JGIM: Journal of General Internal Medicine;Mar2011, Vol. 26 Issue 3, p239 

    Background: Hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) levels predict future complications in chronic hepatitis B (CHB) patients. To determine when to initiate antiviral therapy, treatment guidelines recommend monitoring of HBV DNA and ALT levels at least annually. This study...

  • Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. Man-Fung Yuen; Wai-Kay Seto; James Fung; Danny Ka-Ho Wong; John Chi-Hang Yuen; Ching-Lung Lai // American Journal of Gastroenterology;Jul2011, Vol. 106 Issue 7, p1264 

    OBJECTIVES:We aimed to determine the antiviral potency, viral resistance rate, and clinical safety of 3-year continuous entecavir treatment.METHODS:We determined the cumulative rates of undetectable hepatitis B virus DNA (HBV DNA) levels (<12 IU/ml), hepatitis B e antigen (HBeAg) seroconversion,...

  • New Indications.  // Drug Topics;11/16/98, Vol. 142 Issue 22, p99 

    Reports that the United States (US) Food and Drug Administration has granted extended US marketing approval to Schering-Plough's Intron A, a drug used in treating children with hepatitis B.

  • First nucleotide analog approved for hepatitis B. LoBuono, Charlotte // Drug Topics;10/21/2002, Vol. 146 Issue 20, p15 

    Reports on the approval of the therapeutic option for hepatitis B virus by the U.S. Food and Drug Administration. Recommendation for adefovir dipivoxil for the treatment of the disease; Evidence of active liver disease; Tolerance of patients to the therapy. INSET: TIPS TO REMEMBER..

  • FDA approves Gilead AIDS drug for hepatitis B.  // Gay & Lesbian Times;8/21/2008, Issue 1078, p20 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Gilead Sciences Inc.'s anti-HIV therapy drug for the treatment of hepatitis B.

  • Hepatitis B patients exhibiting mild alanine aminotransferase elevation: A comparative analysis of treatment with and without Bicyclol tablets. YIN ZHANG; YANMING XIE; YIYING ZHANG; YAN LIU; YAN ZHUANG // Biomedical Reports;Nov2016, Vol. 5 Issue 5, p595 

    The aim of the present study was to analyze the medicinal effect of Bicyclol tablets on patients with chronic hepatitis B (CHB) and concomitant mild alanine aminotransferase (ALT) elevation (40-80 IU/l). A retrospective cohort study, which included patients from the hospital information system...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics